Key result
Spironolactone reduced systolic blood pressure by 15 mmHg and diastolic blood pressure by 8 mmHg from baseline in hypertensive patients with a raised aldosterone to renin ratio.
Why the study?
Does oral spironolactone improve blood pressure control in hypertensive patients with a raised aldosterone/renin ratio?
Cohort (n=28)
Open-label
None
No
Does oral spironolactone improve blood pressure control in hypertensive patients with a raised aldosterone/renin ratio?
Effect estimate: -15 mmHg (95% CI 5-25)
Absolute Event Rate: 146% vs 161%
p-value: p=0.007
Spironolactone is a highly effective antihypertensive agent that significantly reduces blood pressure and the need for concurrent medications in hypertensive patients with a raised aldosterone/renin ratio.
No takes yet. Share an insight, caveat, or question.
May support spironolactone in raised ARR hypertension; leaves open need for randomized confirmation.
Lim et al. (1999) conducted a cohort in Hypertension with raised aldosterone to renin ratio (n=28). Spironolactone vs. Baseline was evaluated on Systolic blood pressure (-15 mmHg, 95% CI 5-25, p=0.007). Spironolactone reduced systolic blood pressure by 15 mmHg and diastolic blood pressure by 8 mmHg from baseline in hypertensive patients with a raised aldosterone to renin ratio.